The resale registration is routine post-merger paperwork with no immediate capital raise. The lock-up agreements and the dominant holder's minimal registration suggest limited near-term selling pressure. Monitor for Form 4 filings from selling stockholders as lock-ups expire to gauge actual selling intent.
Price Chart
Executive Summary
Gyre Therapeutics filed Pre-Effective Amendment No. 1 to its S-3 shelf registration, registering 31,302,863 shares of common stock for resale by former Cullgen stockholders and GNI USA. The company is not selling any shares or raising capital; the filing fulfills its contractual Registration Rights Agreement obligations from the Cullgen merger. Lock-up agreements restrict selling for 180 days to 18 months on a portion of shares, and the largest holder (GNI Japan entities, 64.8% owner) is only registering 14.1M of its 86.3M shares, signaling limited near-term overhang.
Key Facts
- 31,302,863 shares of common stock registered for resale by selling stockholders
- No proceeds to Gyre Therapeutics — company not selling any shares
- Filing is a contractual obligation from the May 4, 2026 Cullgen merger (valued at ~$300M)
- Lock-up agreements apply: 1/3 shares locked 180 days, 1/3 for 12 months, 1/3 for 18 months from closing
- GNI Japan-affiliated entities (64.8% holder) registering only 14,090,462 of their 86,323,020 beneficial shares
- As of May 31, 2026, 111,488,849 shares outstanding; last reported price $6.52 on July 10, 2026
- 1,081,332 additional shares registered in this amendment beyond the original 30,221,531
Financial Impact
No capital raised; potential future selling pressure from up to 31.3M shares, but lock-ups and the dominant holder's limited registration mitigate near-term overhang
Risk Factors
- Future resales by selling stockholders could pressure the stock price, especially as lock-up periods expire
- PRC regulatory and HFCAA delisting risk remain as disclosed in the prospectus
- The warrant held by GNI USA ($4,915 exercise price) is deeply out of the money and unlikely to be exercised for cash
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (GYRE) — Batch item 1 | 0001140361-26-028333 |
| Document: ny20070577x2_ex107.htm | 0001140361-26-028333 |
| Document: ny20070577x2_ex5-1.htm | 0001140361-26-028333 |
| Document: ny20070577x2_ex23-1.htm | 0001140361-26-028333 |
| Document: 0001140361-26-028333-index-headers.html | 0001140361-26-028333 |
| Document: 0001140361-26-028333-index.html | 0001140361-26-028333 |
| Document: 0001140361-26-028333.txt | 0001140361-26-028333 |
| S-3/A Filing (GYRE) — Batch item 8 | 0001140361-26-028333 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $5.85 | awaiting T+20 | — | $6.43 (+9.91%) |
Sep 1, 2026 8w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $6.43 (−0.62%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $6.43 (−3.31%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $6.43 (+3.60%) |
Aug 4, 2026 12w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $6.43 (+4.55%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $6.43 (+1.42%) |
Jun 2, 2026 21w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $6.43 (+15.65%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $6.43 (−1.83%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.43 (−18.81%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.43 (−18.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers